JP2002501049A5 - - Google Patents

Download PDF

Info

Publication number
JP2002501049A5
JP2002501049A5 JP2000528540A JP2000528540A JP2002501049A5 JP 2002501049 A5 JP2002501049 A5 JP 2002501049A5 JP 2000528540 A JP2000528540 A JP 2000528540A JP 2000528540 A JP2000528540 A JP 2000528540A JP 2002501049 A5 JP2002501049 A5 JP 2002501049A5
Authority
JP
Japan
Prior art keywords
compound according
compound
tempo
nitrate
free radical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000528540A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002501049A (ja
Filing date
Publication date
Priority claimed from GBGB9801398.0A external-priority patent/GB9801398D0/en
Application filed filed Critical
Publication of JP2002501049A publication Critical patent/JP2002501049A/ja
Publication of JP2002501049A5 publication Critical patent/JP2002501049A5/ja
Pending legal-status Critical Current

Links

JP2000528540A 1998-01-22 1999-01-22 ストレス処置のための一酸化窒素ドナーを含有するピペリジンおよびピロリジン誘導体 Pending JP2002501049A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9801398.0A GB9801398D0 (en) 1998-01-22 1998-01-22 Chemical compounds
GB9801398.0 1998-01-22
PCT/GB1999/000231 WO1999037616A1 (en) 1998-01-22 1999-01-22 Piperidine and pyrrolidine derivatives comprising a nitric oxide donor for treating stress

Publications (2)

Publication Number Publication Date
JP2002501049A JP2002501049A (ja) 2002-01-15
JP2002501049A5 true JP2002501049A5 (enExample) 2006-03-16

Family

ID=10825732

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000528540A Pending JP2002501049A (ja) 1998-01-22 1999-01-22 ストレス処置のための一酸化窒素ドナーを含有するピペリジンおよびピロリジン誘導体

Country Status (9)

Country Link
US (3) US6448267B1 (enExample)
EP (1) EP1124801B1 (enExample)
JP (1) JP2002501049A (enExample)
AT (1) ATE277012T1 (enExample)
AU (1) AU4120699A (enExample)
CA (1) CA2318208C (enExample)
DE (1) DE69920496T2 (enExample)
GB (1) GB9801398D0 (enExample)
WO (1) WO1999037616A1 (enExample)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050137191A1 (en) * 1996-06-04 2005-06-23 Thatcher Gregory R. Nitrate esters and their use for mitigating cellular damage
US6310052B1 (en) 1996-06-04 2001-10-30 Queen's University At Kingston Nitrate esters and their use for neurological conditions
US7914814B2 (en) * 1997-09-17 2011-03-29 Strategic Science & Technologies, Llc Topical delivery of arginine of cause beneficial effects
US7629384B2 (en) * 1997-09-17 2009-12-08 Strategic Science & Technologies, Llc Topical delivery of L-arginine to cause beneficial effects
US6207713B1 (en) * 1997-09-17 2001-03-27 Eric T. Fossel Topical and oral delivery of arginine to cause beneficial effects
GB2349385A (en) * 1999-04-30 2000-11-01 Teijin Ltd Organic nitrates and nitrites useful against heart disease
US7135498B1 (en) 1999-06-14 2006-11-14 Henry Ford Health System Nitric oxide donors for inducing neurogenesis
IL147112A0 (en) * 1999-06-14 2002-08-14 Ford Henry Health System Nitric oxide donors for inducing neurogenesis
KR20010038797A (ko) * 1999-10-27 2001-05-15 김길환 홍국을 이용한 일산화질소 생성제 조성물 및 이를 이용한 약품 조성물
SE9903985D0 (sv) * 1999-11-03 1999-11-03 Aga Ab Use of nitric oxide
US6601580B1 (en) * 2000-06-28 2003-08-05 The General Hospital Corporation Enhancing therapeutic effectiveness of nitric oxide inhalation
UY26893A1 (es) * 2000-08-22 2002-03-22 Boehringer Ingelheim Pharma Combinación farmacéutica de antagonistas de la angiotensina ii e inhibidores de la enzima de conversión de la angiotensina i
US20020072512A1 (en) * 2000-12-08 2002-06-13 Metaphore Pharmaceuticals, Inc Method of preventing and treating HIV-mediated central nervous system damage
US20020151431A1 (en) * 2001-01-26 2002-10-17 Jeff Thornton Recovery method
AU2002236861A1 (en) * 2001-01-26 2002-08-06 Metaphore Pharmaceuticals, Inc. Method of treatment of neurodegenerative disorders using pentaaza-macrocyclic ligand complexes
US20030045461A1 (en) 2001-09-06 2003-03-06 Jen-Chang Hsia Composition and methods of esterified nitroxides gated with carboxylic acids
WO2003053425A1 (en) * 2001-12-10 2003-07-03 Yansheng Du Treatment of neurodegenerative and cardiovascular disorders
WO2003088961A1 (en) 2002-04-19 2003-10-30 Yissum Research Development Company Of The Hebrew University Of Jerusalem Beta-agonist compounds comprising nitric oxide donor groups and reactive oxygen species scavenger groups and their use in the treatment of respiratory disorders
WO2003095623A2 (en) * 2002-05-10 2003-11-20 The Trustees Of Columbia University In The City Of New York Genetically engineered cell lines and systems for propagating varicella zoster virus and methods of use thereof
WO2004037843A2 (en) * 2002-10-25 2004-05-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Steroid compounds comprising superoxide dismutase mimic groups and nitric oxide donor groups, and their use in the preparation of medicaments
WO2004047837A2 (en) * 2002-11-22 2004-06-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Beta-blockers having antioxidant and nitric oxide-donor activity
WO2004050084A2 (en) * 2002-11-29 2004-06-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ace-inhibitors having antioxidant and nitricoxid-donor activity
US20060264408A1 (en) * 2003-03-06 2006-11-23 Haj-Yehia Abdullah I Sod minic multifunctional compounds for treating inflammatory bowel disease
EP1732577B1 (en) * 2004-02-23 2013-04-10 Strategic Science & Technologies, LLC Topical delivery of l-arginine to improve body and skin appearance
US20110028548A1 (en) * 2004-04-19 2011-02-03 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
JP2007532697A (ja) * 2004-04-19 2007-11-15 ストラテジック サイエンス アンド テクノロジーズ， エルエルシー 局所的血流増大の有益な効果
US9226909B2 (en) 2004-04-19 2016-01-05 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
US20090105336A1 (en) * 2004-04-19 2009-04-23 Strategic Science & Technologies, Llc Beneficial Effects of Increasing Local Blood Flow
EP1766014A4 (en) 2004-06-03 2008-12-10 Athlomics Pty Ltd AGENTS AND METHODS FOR THE DIAGNOSIS OF STRESS
US20070254900A1 (en) * 2004-08-11 2007-11-01 Kassab Ghassan S Treatments for Congestive Heart Failure
WO2006037050A2 (en) * 2004-09-24 2006-04-06 Metaphore Pharmaceuticals, Inc. Methods for treating congestive heart failure
US20090062338A1 (en) * 2005-02-02 2009-03-05 Louis Habash Nitroxides for use in treating or preventing cardiovascular disease
JP2008528694A (ja) 2005-02-02 2008-07-31 ミトス・ファーマシューティカルズ・インコーポレーテッド 糖尿病の治療または予防において使用するためのニトロキシド類
CA2597422A1 (en) * 2005-02-16 2007-08-02 Nitromed, Inc. Organic nitric oxide donor salts of antimicrobial compounds, compositions and methods of use
US20090215838A1 (en) * 2005-03-09 2009-08-27 Nitromed, Inc. Organic nitric oxide enhancing salts of angiotensin ii antagonists, compositions and methods of use
EP1883614A4 (en) * 2005-05-23 2010-04-14 Nicox Sa ORGANIC NITRIC OXIDES IMPROVING SALTS FROM NON-SUBSTITUTE INFLAMMATORY COMPOUNDS AND COMPOSITIONS AND USES THEREOF
EP2669269B1 (en) 2005-05-27 2019-05-22 The University of North Carolina At Chapel Hill Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
US8021679B2 (en) 2005-08-25 2011-09-20 Medtronic Vascular, Inc Nitric oxide-releasing biodegradable polymers useful as medical devices and coatings therefore
WO2007075541A2 (en) * 2005-12-20 2007-07-05 Nitromed, Inc. Nitric oxide enhancing glutamic acid compounds, compositions and methods of use
WO2007075542A2 (en) * 2005-12-22 2007-07-05 Nitromed, Inc. Nitric oxide enhancing pyruvate compounds, compositions and methods of use
AU2006343591A1 (en) * 2006-05-11 2007-11-22 Bell Helicopter Textron, Inc. Device and method for repairing structural components
US20090311189A1 (en) * 2006-05-12 2009-12-17 Massachusetts Institute Of Technology Temperature-jump dynamic nuclear polarization
US7985594B2 (en) * 2006-05-12 2011-07-26 Massachusetts Institute Of Technology Biradical polarizing agents for dynamic nuclear polarization
US8241619B2 (en) 2006-05-15 2012-08-14 Medtronic Vascular, Inc. Hindered amine nitric oxide donating polymers for coating medical devices
JP5191702B2 (ja) * 2006-08-01 2013-05-08 三菱レイヨン株式会社 Ｎ−オキシル化合物、その製造方法および重合防止方法
US7811600B2 (en) * 2007-03-08 2010-10-12 Medtronic Vascular, Inc. Nitric oxide donating medical devices and methods of making same
US8273828B2 (en) * 2007-07-24 2012-09-25 Medtronic Vascular, Inc. Methods for introducing reactive secondary amines pendant to polymers backbones that are useful for diazeniumdiolation
US20090222088A1 (en) * 2008-02-29 2009-09-03 Medtronic Vascular, Inc. Secondary Amine Containing Nitric Oxide Releasing Polymer Composition
US20090232863A1 (en) * 2008-03-17 2009-09-17 Medtronic Vascular, Inc. Biodegradable Carbon Diazeniumdiolate Based Nitric Oxide Donating Polymers
US20090232868A1 (en) * 2008-03-17 2009-09-17 Medtronic Vascular, Inc. Nitric Oxide Releasing Polymer Composition
US8158187B2 (en) * 2008-12-19 2012-04-17 Medtronic Vascular, Inc. Dry diazeniumdiolation methods for producing nitric oxide releasing medical devices
US8709465B2 (en) * 2009-04-13 2014-04-29 Medtronic Vascular, Inc. Diazeniumdiolated phosphorylcholine polymers for nitric oxide release
EP2418945B1 (en) 2009-04-15 2018-12-05 BMG PHARMA S.p.A. Mineral salt-sulfonic acid compositions and methods of use
US11684624B2 (en) 2009-06-24 2023-06-27 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
EP2445493A1 (en) 2009-06-24 2012-05-02 Strategic Science & Technologies, LLC Topical composition containing naproxen
CN102481275B (zh) 2009-06-24 2014-07-23 战略科学技术有限公司 含有布洛芬的表面组合物
US12138268B2 (en) 2009-06-24 2024-11-12 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
WO2011022652A1 (en) 2009-08-21 2011-02-24 Novan, Inc. Topical gels
EP2467173B8 (en) 2009-08-21 2019-06-19 Novan, Inc. Wound dressings, methods of using the same and methods of forming the same
WO2011092690A1 (en) 2010-01-26 2011-08-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Compositions and methods for prevention and treatment of pulmonary hypertension
US8591876B2 (en) 2010-12-15 2013-11-26 Novan, Inc. Methods of decreasing sebum production in the skin
CN103442723A (zh) 2010-12-29 2013-12-11 战略科学与技术有限责任公司 治疗变态反应和其它适应症的系统和方法
EP2658551B1 (en) 2010-12-29 2020-07-01 Strategic Science & Technologies, LLC Treatment of erectile dysfunction and other indications
WO2012093383A1 (en) 2011-01-04 2012-07-12 Radikal Therapeutics Inc. Compositions and methods for treatment of sepsis and related conditions
WO2012118819A2 (en) 2011-02-28 2012-09-07 Novan, Inc. Nitric oxide-releasing s-nitrosothiol-modified silica particles and methods of making the same
WO2013005216A1 (en) 2011-07-05 2013-01-10 Radikal Therapeutics Inc. Compositions and methods for treatment of renal ischemia-reperfusion injury
US8715621B2 (en) 2012-03-15 2014-05-06 Massachusetts Institute Of Technology Radical polarizing agents for dynamic nuclear polarization
WO2013190497A2 (en) 2012-06-21 2013-12-27 Radikal Therapeutics Inc. Compositions and methods for treatment of inflammatory diseases of the lung
PT2964218T (pt) 2013-03-05 2018-03-26 Radikal Therapeutics Inc Pró-fármacos de derivados de nitróxido multifuncional e utilizações dos mesmos
WO2016151591A1 (en) * 2015-03-26 2016-09-29 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Nitroxide radicals for the treatment of diseases of the respiratory tract
CA3204594A1 (en) 2020-12-15 2022-06-23 Life Technologies Corporation Chemically defined serum albumin substitutes

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3752812A (en) 1970-02-05 1973-08-14 Pfizer 2-trifluoromethylquinoxalinedi n oxides
US4563446A (en) 1983-07-27 1986-01-07 Takeda Chemical Industries, Ltd. Thromboxane synthetase inhibiting 3-(1-alkenyl) pyridines
DE3328365A1 (de) * 1983-08-03 1985-02-21 Schering AG, 1000 Berlin und 4709 Bergkamen Neue diagnostische mittel
US5352442A (en) 1985-07-18 1994-10-04 Proctor Peter H Topical tempo
US5890387A (en) 1989-08-24 1999-04-06 Aquaform Inc. Apparatus and method for forming and hydropiercing a tubular frame member
IT1256450B (it) 1992-11-26 1995-12-05 Soldato Piero Del Esteri nitrici con attivita' farmacologica e procedimento per la loro preparazione
JP3775796B2 (ja) 1993-10-06 2006-05-17 ニコックス エス エイ 抗炎症活性及び／又は鎮痛活性を有する硝酸エステル類及びそれらの製造方法
US6143746A (en) 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
RU2145595C1 (ru) 1994-05-10 2000-02-20 Никокс С.А. Нитроксисоединения и фармацевтическая композиция на их основе, имеющие противовоспалительную, анальгетическую и антитромбоцитарную активности
US5703073A (en) 1995-04-19 1997-12-30 Nitromed, Inc. Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs
AU6031096A (en) 1995-06-05 1996-12-24 Duke University Nitrosylated and nitrated superoxide oxidants and reductants
IT1276071B1 (it) 1995-10-31 1997-10-24 Nicox Ltd Compositi ad attivita' anti-infiammatoria
IT1282686B1 (it) 1996-02-26 1998-03-31 Nicox Sa Composti in grado di ridurre la tossicita' da farmaci
US6140309A (en) 1996-03-12 2000-10-31 University Of South Florida Vasoactive effects and free radical generation by β-amyloid peptides
US5824669A (en) 1996-03-22 1998-10-20 Nitromed, Inc. Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders
US5977090A (en) 1996-09-27 1999-11-02 Guilford Pharmaceuticals Inc. Pharmaceutical compositions and methods of treating compulsive disorders using NAALADase inhibitors
US5885842A (en) 1996-11-08 1999-03-23 Medinox, Inc. Methods for the detection of nitric oxide in fluid media
IT1295694B1 (it) 1996-11-14 1999-05-27 Nicox Sa Nitrossi derivati per la preparazione di medicamenti ad attivita antitrombinica
IL120531A (en) * 1997-03-26 2006-12-31 Yissum Res Dev Co Nitric oxide donors and pharmaceutical compositions containing them
US6043252A (en) 1997-05-05 2000-03-28 Icos Corporation Carboline derivatives
US5916910A (en) 1997-06-04 1999-06-29 Medinox, Inc. Conjugates of dithiocarbamates with pharmacologically active agents and uses therefore
IT1292377B1 (it) 1997-06-19 1999-02-08 Nicox Sa Composizioni farmaceutiche a base di prostaglandine
JP3377731B2 (ja) * 1997-09-29 2003-02-17 三菱重工業株式会社 高性能水素分離膜
AU2662799A (en) 1998-02-13 1999-08-30 Medinox, Inc. Modified pharmacologically active agents and improved therapeutic methods employing same
IN188837B (enExample) 1998-05-22 2002-11-09 Torrent Pharmaceuticals Ltd
US6093743A (en) 1998-06-23 2000-07-25 Medinox Inc. Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor
US6265420B1 (en) 1998-06-23 2001-07-24 Medinox, Inc. Use of nitric oxide scavengers to treat side effects caused by therapeutic administration of sources of nitric oxide
WO2000015639A1 (en) 1998-09-16 2000-03-23 Icos Corporation Carboline derivatives as cgmp phosphodiesterase inhibitors
CA2352144A1 (en) 1998-11-25 2000-06-02 Yissum Research Development Company Of The Hebrew University In Jerusale M Scavenger compounds
US6395736B1 (en) 1998-12-14 2002-05-28 Cellegy Pharmaceuticals, Inc. Compositions and methods for the treatment of anorectal disorders
GB2349385A (en) 1999-04-30 2000-11-01 Teijin Ltd Organic nitrates and nitrites useful against heart disease
US6417207B1 (en) 1999-05-12 2002-07-09 Nitromed, Inc. Nitrosated and nitrosylated potassium channel activators, compositions and methods of use
AU781084B2 (en) 1999-07-28 2005-05-05 Board Of Trustees Of The Leland Stanford Junior University Nicotine in therapeutic angiogenesis and vasculogenesis
SE9903985D0 (sv) 1999-11-03 1999-11-03 Aga Ab Use of nitric oxide

Similar Documents

Publication Publication Date Title
JP2004532209A5 (enExample)
JP2006509749A5 (enExample)
JP2005539088A5 (enExample)
JP2008528658A5 (enExample)
RU2004125279A (ru) Новые пептиды, как ингибиторы ns3-серинпротеазы вируса гепатита c
JPH101495A5 (enExample)
JP2002069004A (ja) 末梢性活性抗痛覚過敏オピエート
DK1487829T3 (da) Thiadizolylpiperazinderivater, der er nyttige til behandling eller forebyggelse af smerte
JP2006514626A5 (enExample)
JP2003506406A5 (enExample)
AR012960A1 (es) Una composicion farmaceutica para utilizar en el tratamiento del sindrome de intestino irritable que comprende compuestos vainillinicos; el uso decompuestos vainillinicos, un metodo de tratamiento del sindrome de intestino irritable; un proceso para la fabricacion de dicha composicion
JP2021152063A5 (enExample)
RU99105567A (ru) Производные пропионовой кислоты и их использование
JP2004538303A5 (enExample)
JP2008505117A5 (enExample)
JP2002519425A5 (enExample)
JP2008534453A5 (enExample)
CA2281426A1 (en) Substituted indole compounds as anti-inflammatory and analgesic agents
JP2003502367A5 (enExample)
JP2007502817A5 (enExample)
JP2005533013A5 (enExample)
RU2002130247A (ru) Производные оксадиазола, обладающие противоопухолевым действием
NO20064811L (no) 4-(5-aminometyl-2-fluor-fenyl)-piperidin-1-yl]-(4-brom-3-metyl-5-propoksy-tiofen-2-yl)-metanonhydroklorid som en inhibitor av mastcelletryptase
JP2004530699A5 (enExample)
RU2007131435A (ru) Противоопухолевое средство